相似文献
1
Lipids in Chronic Obstructive Pulmonary Disease: A Target for Future Therapy?
Am J Respir Cell Mol Biol. 2020 Mar;62(3):273-274. doi: 10.1165/rcmb.2019-0338ED.
2
Disease of the airways in chronic obstructive pulmonary disease.
Eur Respir J Suppl. 2001 Dec;34:41s-49s. doi: 10.1183/09031936.01.00234601.
3
Clinical use of the measurement of airway resistance during spontaneous respiration.
Respiration. 1984;45(4):360-71. doi: 10.1159/000194644.
4
[Chronic obstructive lung disease (COPD)].
Med Klin (Munich). 2006 Jul 15;101(7):559-70; quiz 571-2. doi: 10.1007/s00063-006-1078-9.
5
Visualized changes in respiratory resistance and reactance along a time axis in smokers: a cross-sectional study.
Respir Investig. 2013 Sep;51(3):166-74. doi: 10.1016/j.resinv.2013.02.006. Epub 2013 May 4.
6
Involvement of type II pneumocytes in the pathogenesis of chronic obstructive pulmonary disease.
Respir Med. 2010 Oct;104(10):1391-5. doi: 10.1016/j.rmed.2010.06.018.
7
[Associations between TGF-β1 G/A and TNF-α 308 G/A gene polymorphisms with airway resistance in chronic obstructive pulmonary disease].
Tuberk Toraks. 2013;61(1):1-11. doi: 10.5578/tt.4390.
8
Chronic obstructive pulmonary disease: knowing what we mean, meaning what we say.
Indian J Chest Dis Allied Sci. 2008 Jan-Mar;50(1):89-95.
9
Pathophysiology of airflow limitation in chronic obstructive pulmonary disease.
Lancet. 2004;364(9435):709-21. doi: 10.1016/S0140-6736(04)16900-6.
10
Airway basal cells. The "smoking gun" of chronic obstructive pulmonary disease.
Am J Respir Crit Care Med. 2014 Dec 15;190(12):1355-62. doi: 10.1164/rccm.201408-1492PP.
引用本文的文献
1
Linking Lipid Metabolism and Immune Function: New Insights into Chronic Respiratory Diseases.
Pathophysiology. 2025 Jun 6;32(2):26. doi: 10.3390/pathophysiology32020026.
2
Exhaled breath particles as a novel tool to study lipid composition of epithelial lining fluid from the distal lung.
BMC Pulm Med. 2023 Nov 3;23(1):423. doi: 10.1186/s12890-023-02718-8.
3
Metabolomics of Respiratory Diseases.
Handb Exp Pharmacol. 2023;277:339-365. doi: 10.1007/164_2022_614.
4
Update in Chronic Obstructive Pulmonary Disease 2020.
Am J Respir Crit Care Med. 2021 Jul 1;204(1):14-22. doi: 10.1164/rccm.202102-0253UP.
本文引用的文献
1
Airway Resistance Caused by Sphingomyelin Synthase 2 Insufficiency in Response to Cigarette Smoke.
Am J Respir Cell Mol Biol. 2020 Mar;62(3):342-353. doi: 10.1165/rcmb.2019-0133OC.
2
Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies.
Pharmacol Ther. 2019 Jun;198:160-188. doi: 10.1016/j.pharmthera.2019.02.013. Epub 2019 Feb 26.
3
Bioactive Sphingolipids in the Pathogenesis of Chronic Obstructive Pulmonary Disease.
Ann Am Thorac Soc. 2018 Dec;15(Suppl 4):S249-S252. doi: 10.1513/AnnalsATS.201809-592MG.
4
Sphingomyelin synthase 2 overexpression promotes cisplatin-induced apoptosis of HepG2 cells.
Oncol Lett. 2018 Jan;15(1):483-488. doi: 10.3892/ol.2017.7309. Epub 2017 Oct 31.
5
Sphingomyelin Metabolism Is a Regulator of K-Ras Function.
Mol Cell Biol. 2018 Jan 16;38(3). doi: 10.1128/MCB.00373-17. Print 2018 Feb 1.
6
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary.
Am J Respir Crit Care Med. 2017 Mar 1;195(5):557-582. doi: 10.1164/rccm.201701-0218PP.
7
Recent advances in pre-clinical mouse models of COPD.
Clin Sci (Lond). 2014 Feb;126(4):253-65. doi: 10.1042/CS20130182.
8
The role of sphingolipids in respiratory disease.
Ther Adv Respir Dis. 2011 Oct;5(5):325-44. doi: 10.1177/1753465811406772.
9
An overview of sphingolipid metabolism: from synthesis to breakdown.
Adv Exp Med Biol. 2010;688:1-23. doi: 10.1007/978-1-4419-6741-1_1.
10
The domain responsible for sphingomyelin synthase (SMS) activity.
Biochim Biophys Acta. 2008 Oct;1781(10):610-7. doi: 10.1016/j.bbalip.2008.07.002. Epub 2008 Jul 23.
Zotero 插件